196TiP - PREM-LC: Development and pilot testing of a patient reported experience measure in lung cancer

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Thoracic malignancies
Presenter Katy Burns
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors K. Burns1, A.S. Harle2, F. Blackhall1, J. Fenemore2, J. Yorke1
  • 1Institute Of Cancer Sciences, The University of Manchester, M20 3LJ - Manchester/GB
  • 2Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB



The National Health Service (NHS) in the UK has placed the improvement of patient experience at the forefront of its priorities. The aim of this approach is to improve health outcomes for patients. The NHS Patient Experience Framework forms a set of criteria which should be used to guide the measurement of patient experience inclusive of emotional support, continuity of care and respect for patient-centred values. Patient experience data can be generated in a number of ways; the most frequently adopted method is questionnaire surveys with simple tools such as the Friends and Family Test. These tools are administered to all NHS patients regardless of their illness. There has been significant expansion in the development and application of patient reported questionnaires to measure care experience, (termed Patient Reported Experience Measures, PREM) and can be a major indicator of healthcare quality. There is currently no available PREM for patients with lung cancer (LC). The development of a PREM for LC will facilitate specific examination of the experiences of patients with this disease at various time points in their clinical pathway. Through routine use of a specific LC PREM, NHS service improvements can be identified and implemented with the potential to improve quality of life and health outcomes for patients with LC.

Trial design

This is a single centre, four stage, non-interventional study to develop and pilot test a PREM in the lung cancer patient population for clinical application. Stage 1 (in progress): Qualitative interviews are conducted with patients (15 to date) who are at different stages in their care pathway. Stage II: Items for inclusion in the PREM-LC will be identified from interview transcripts. A draft item list will be scrutinised for clarity and ease of understanding through cognitive interviews with ∼7 patients. Stage III: A draft PREM-LC will be administered to ∼100 patients. Patients will also complete validated experience and quality of life tools. ∼50 patients will repeat the draft PREM-LC 7 days later with a Global Rating of Change scale. Stage IV: The final PREM-LC will be pilot tested with ∼20 patients to assess its feasibility for routine collection of patient experience data. Preliminary results will be presented.

Clinical trial identification

15_DOG07_200 September 2015

Legal entity responsible for the study

The University of Manchester


The Christie NHS Foundation Trust


All authors have declared no conflicts of interest.